EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Paclitaxel liposome with anti–HER-2 drugs as first-line therapy for recurrent/metastatic HER-2–positive breast cancer: a real-world study

Jian Yue, Jin Zhang, Shusen Wang, Lili Zhang, Xiaohua Zeng, Huiping Li, Fei Ma, Zhouguang Hui

Holistic Integrative Oncology · 11.08.2026 · 5 (1)

DOI: 10.1007/s44178-026-00283-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Holistic Integrative Oncology, online erschienen am 11.08.2026. Verfasst von Jian Yue und 7 weiteren Autor:innen. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clinical evidence for the use of paclitaxel liposome combined with anti–HER-2 drugs as first-line salvage treatment for HER-2–positive advanced breast cancer (BC) remains limited.

Methods

In this retrospective, single-arm, real-world study, patients with HER-2–positive advanced BC who received paclitaxel liposome combined with anti–HER-2 agents as first-line salvage therapy between January 2013 and December 2022 were identified from the National Cancer Center Oncology Information Database. The primary outcomes were real-world progression-free survival (rwPFS) and overall survival (OS).

Results

A total of 526 eligible patients were included, with a median age of 53.0 years; 296 (56.3%) were hormone receptor (HR)–positive. Treatment regimens mainly included paclitaxel liposome plus trastuzumab (53.2%), paclitaxel liposome plus trastuzumab and pertuzumab (32.1%), and paclitaxel liposome plus trastuzumab and tyrosine kinase inhibitors (TKIs) (11.0%). Median follow-up was 856 days. The overall median rwPFS and OS were 22.1 months (95% CI, 20.0 to 25.7) and 57.9 months (95% CI, 52.2 to 62.9), respectively. The overall rwORR was 55.9%, and rwDCR was 94.7%. Among HR + and HR–subgroups, median rwPFS was 24.5 months (95% CI, 20.8 to 28.7) and 17.7 months (95% CI, 14.7 to 21.8), respectively; mOS was 60.5 months (95% CI, 50.7 to not reached) and 53.5 months (95% CI, 49.9 to 63.3), respectively. Common adverse events included myelosuppression, gastrointestinal reactions, hepatic dysfunction, and neurotoxicity.

Conclusions

In real-world setting, paclitaxel liposome combined with various anti–HER-2 drugs demonstrated favorable effect and safety in patients with HER-2–positive advanced BC, regardless of HR status.

Trial registration

Registered on ClinicalTrials.gov under NCT06481553 on July 01, 2024 (retrospectively registered; https://clinicaltrials.gov/study/NCT06481553 ).

Zitieren

APA

Yue, J., Zhang, J., Wang, S., Zhang, L., Zeng, X., Li, H., Ma, F., & Hui, Z. (2026). Paclitaxel liposome with anti–HER-2 drugs as first-line therapy for recurrent/metastatic HER-2–positive breast cancer: a real-world study. Holistic Integrative Oncology, 5(1). https://doi.org/10.1007/s44178-026-00283-8

Vancouver

Yue J, Zhang J, Wang S, Zhang L, Zeng X, Li H, et al. Paclitaxel liposome with anti–HER-2 drugs as first-line therapy for recurrent/metastatic HER-2–positive breast cancer: a real-world study. Holistic Integrative Oncology. 2026;5(1). doi:10.1007/s44178-026-00283-8

BibTeX
@article{Yue2026,
  author = {Yue, Jian and Zhang, Jin and Wang, Shusen and Zhang, Lili and Zeng, Xiaohua and Li, Huiping and Ma, Fei and Hui, Zhouguang},
  title = {Paclitaxel liposome with anti–HER-2 drugs as first-line therapy for recurrent/metastatic HER-2–positive breast cancer: a real-world study},
  journal = {Holistic Integrative Oncology},
  year = {2026},
  volume = {5},
  number = {1},
  doi = {10.1007/s44178-026-00283-8}
}
Kostenlos starten →